Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)

European Urology

Volumn 55, Issue 1, 2009, Pages 14-22

  Schröder, Fritz H ^a   Kurth, Karl Heinz ^b   Fossa, Sophie D ^c   Hoekstra, Wytse ^d   Karthaus, Peter P ^e   De Prijck, Linda ^f   Collette, Laurence ^f  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Medicenter   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^f EORTC DATA CENTER   (Belgium)

Author keywords

Endocrine treatment timing; Node positive; Prostate cancer; Randomized trial

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; GONADORELIN AGONIST; GOSERELIN;

ARTICLE; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CAUSE OF DEATH; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; EARLY INTERVENTION; EUROPE; FOLLOW UP; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; CASTRATION; CLINICAL PROTOCOLS; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 56249134154     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.09.008     Document Type: Article

References (16)

1. Kramer S.A., Cline Jr. W.A., Farnham R., et al. Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 125 (1981) 817-819
2. Van Aubel O.G.J.M., Hoekstra W.J., and Schröder F.H. Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 134 (1985) 292-294
3. Carpentier P.J., and Schröder F.H. Transrectal ultrasonography in the follow-up of prostatic carcinoma patients: a new prognostic parameter?. J Urol 131 (1984) 903-905
4. Smith P.H., Suciu S., Robinson M.R., et al. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostate cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol 136 (1986) 619-623
5. Mellinger G.T., and Blackard C. The incidence of cardiovascular complications in prostate cancer. Life Sciences Monographs 1 (1969), Pergamon Press, Oxford, UK p. 65-76
6. Byar D.P. VACURG studies on prostatic cancer and its treatment. Urologic Pathology: The Prostate (1977), Lea & Febiger, Philadelphia 241-267
7. Schröder F.H., Kurth K.H., Fosså S.D., et al., Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumour: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 172 (2004) 923-927
8. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 16 (1988) 1141-1154
9. Cox D.R. Regression models and life-tables. J R Statist Soc B34 (1972) 187-202
10. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
11. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
12. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. New Eng J Med 341 (1999) 1781-1788
13. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
14. Lawton C.A., Bae K., Pilepich M., Hanks G., and Shipley W. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-102. Int J Radiat Oncol Biol Phys 70 (2008) 437-441
15. Peto R, Dalesio O, PCTCG group [Federation of European Cancer Societies ECCO 12, Copenhagen Web site]. 2004. Available at: http://supply.lanl.gov/property/ecco/History/2004/presentations2004/default.shtml. Accessed August 8, 2008.
16. Schröder F.H. Early versus delayed endocrine therapy for prostate cancer. Endocrine-Related Cancer 14 (2007) 1-11